Appili Therapeutics Inc. (APLIF)
OTCMKTS
· Delayed Price · Currency is USD
0.0140
0.00 (0.00%)
Jul 11, 2025, 4:00 PM EDT
Appili Therapeutics Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| 0.1 | 0.83 | 0.33 | 1.39 | - | Upgrade
| |
Revenue Growth (YoY) | -87.86% | 147.59% | -75.97% | - | - | Upgrade
|
Gross Profit | 0.1 | 0.83 | 0.33 | 1.39 | - | Upgrade
|
Selling, General & Admin | 2.86 | 3.26 | 4.62 | 5.32 | 5.44 | Upgrade
|
Research & Development | 7.32 | 5.62 | 3.62 | 20.74 | 10.22 | Upgrade
|
Operating Expenses | 10.19 | 8.88 | 8.25 | 26.07 | 15.66 | Upgrade
|
Operating Income | -10.09 | -8.05 | -7.91 | -24.68 | -15.66 | Upgrade
|
Interest Expense | -2.95 | -1.63 | -0.95 | -1.55 | -0.12 | Upgrade
|
Interest & Investment Income | 0 | 0.02 | 0.03 | 0.03 | 0.12 | Upgrade
|
Currency Exchange Gain (Loss) | -0.33 | 0.07 | -0.36 | 0.06 | - | Upgrade
|
Other Non Operating Income (Expenses) | 10.76 | 5.89 | 0.14 | 1.06 | 1.34 | Upgrade
|
EBT Excluding Unusual Items | -2.61 | -3.71 | -9.06 | -25.08 | -14.33 | Upgrade
|
Other Unusual Items | - | - | -0.14 | - | - | Upgrade
|
Pretax Income | -2.61 | -3.71 | -9.21 | -25.08 | -14.33 | Upgrade
|
Income Tax Expense | 0.02 | 0.07 | 0.04 | 0.04 | - | Upgrade
|
Net Income | -2.62 | -3.78 | -9.24 | -25.12 | -14.33 | Upgrade
|
Net Income to Common | -2.62 | -3.78 | -9.24 | -25.12 | -14.33 | Upgrade
|
Shares Outstanding (Basic) | 121 | 121 | 114 | 67 | 59 | Upgrade
|
Shares Outstanding (Diluted) | 121 | 121 | 114 | 67 | 59 | Upgrade
|
Shares Change (YoY) | - | 6.63% | 70.43% | 12.76% | 72.40% | Upgrade
|
EPS (Basic) | -0.02 | -0.03 | -0.08 | -0.38 | -0.24 | Upgrade
|
EPS (Diluted) | -0.02 | -0.03 | -0.08 | -0.38 | -0.24 | Upgrade
|
Free Cash Flow | 0.87 | -2.49 | -10.1 | -19.08 | -11.46 | Upgrade
|
Free Cash Flow Per Share | 0.01 | -0.02 | -0.09 | -0.29 | -0.19 | Upgrade
|
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | Upgrade
|
Operating Margin | -10040.58% | -972.94% | -2368.29% | -1774.56% | - | Upgrade
|
Profit Margin | -2613.12% | -456.96% | -2765.90% | -1806.18% | - | Upgrade
|
Free Cash Flow Margin | 862.63% | -301.44% | -3022.65% | -1372.07% | - | Upgrade
|
EBITDA | -10.07 | -8.04 | -7.91 | -24.67 | -15.65 | Upgrade
|
D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
EBIT | -10.09 | -8.05 | -7.91 | -24.68 | -15.66 | Upgrade
|
Revenue as Reported | 0.1 | 0.84 | 0.36 | 1.42 | 0.12 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.